Cadila Healthcare inks settlement and license pact with Somaxon

20 Jul 2012 Evaluate

Cadila Healthcare, a global pharmaceutical company, and Zydus Pharmaceuticals (USA, a leading generic pharmaceutical company in the United States, have entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.

Under the settlement and license agreement, Cadila Healthcare and Zydus Pharmaceuticals (USA), have the right to begin selling a generic version of Silenor 180 days after another party begins selling a generic version of Silenor in the United States under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon’s patents are not infringed, invalid or unenforceable, or earlier under certain circumstances.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

904.00 -7.50 (-0.82%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×